Rockwell Medical Inc
Rockwell Medical, Inc., together with its subsidiaries, develops, manufactures, commercializes, and distributes various hemodialysis products for dialysis providers worldwide. The company offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterily… Read more
Rockwell Medical Inc (RMTI) - Net Assets
Latest net assets as of September 2025: $37.02 Million USD
Based on the latest financial reports, Rockwell Medical Inc (RMTI) has net assets worth $37.02 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($57.49 Million) and total liabilities ($20.47 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $37.02 Million |
| % of Total Assets | 64.4% |
| Annual Growth Rate | 11.56% |
| 5-Year Change | -4.64% |
| 10-Year Change | -47.71% |
| Growth Volatility | 2196.27 |
Rockwell Medical Inc - Net Assets Trend (1997–2024)
This chart illustrates how Rockwell Medical Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Rockwell Medical Inc (1997–2024)
The table below shows the annual net assets of Rockwell Medical Inc from 1997 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $32.59 Million | +53.05% |
| 2023-12-31 | $21.29 Million | +50.94% |
| 2022-12-31 | $14.11 Million | +456.45% |
| 2021-12-31 | $2.54 Million | -92.58% |
| 2020-12-31 | $34.17 Million | +68.16% |
| 2019-12-31 | $20.32 Million | -25.50% |
| 2018-12-31 | $27.28 Million | -17.12% |
| 2017-12-31 | $32.91 Million | -37.85% |
| 2016-12-31 | $52.96 Million | -15.02% |
| 2015-12-31 | $62.32 Million | -9.29% |
| 2014-12-31 | $68.70 Million | +11436.24% |
| 2013-12-31 | $595.54K | +105.98% |
| 2012-12-31 | $-9.96 Million | -154.60% |
| 2011-12-31 | $18.24 Million | -40.25% |
| 2010-12-31 | $30.54 Million | +4.14% |
| 2009-12-31 | $29.32 Million | +148.06% |
| 2008-12-31 | $11.82 Million | -34.19% |
| 2007-12-31 | $17.96 Million | +114.48% |
| 2006-12-31 | $8.37 Million | +117.80% |
| 2005-12-31 | $3.84 Million | +12.34% |
| 2004-12-31 | $3.42 Million | +7.89% |
| 2003-12-31 | $3.17 Million | +4.16% |
| 2002-12-31 | $3.05 Million | +17.29% |
| 2001-12-31 | $2.60 Million | -9.25% |
| 2000-12-31 | $2.86 Million | -20.52% |
| 1999-12-31 | $3.60 Million | -21.74% |
| 1998-12-31 | $4.60 Million | +170.59% |
| 1997-12-31 | $1.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Rockwell Medical Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 39577800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | 0.01% |
| Other Comprehensive Income | $54.00K | 0.17% |
| Other Components | $430.21 Million | 1320.22% |
| Total Equity | $32.59 Million | 100.00% |
Rockwell Medical Inc Competitors by Market Cap
The table below lists competitors of Rockwell Medical Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cytosorbents Crp
NASDAQ:CTSO
|
$37.35 Million |
|
Hwa Fong Rubber (Thailand) Public Company Limited
BK:HFT
|
$37.35 Million |
|
NVH Korea Inc
KQ:067570
|
$37.36 Million |
|
SEOHAN Const. & Eng.co.Ltd
KQ:011370
|
$37.37 Million |
|
Ubiqconn Technology, Inc.
TW:6928
|
$37.35 Million |
|
Kayseri Seker Fabrikasi AS
IS:KAYSE
|
$37.35 Million |
|
Turmalina Metals Corp
OTCQB:TBXXF
|
$37.32 Million |
|
RF Acquisition Corp II Ordinary Shares
NASDAQ:RFAI
|
$37.31 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rockwell Medical Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 21,291,000 to 32,586,000, a change of 11,295,000 (53.1%).
- Net loss of 480,000 reduced equity.
- New share issuances of 10,181,000 increased equity.
- Other comprehensive income increased equity by 55,000.
- Other factors increased equity by 1,539,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-480.00K | -1.47% |
| Share Issuances | $10.18 Million | +31.24% |
| Other Comprehensive Income | $55.00K | +0.17% |
| Other Changes | $1.54 Million | +4.72% |
| Total Change | $- | 53.05% |
Book Value vs Market Value Analysis
This analysis compares Rockwell Medical Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.01x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.28x to 1.01x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-12-31 | $3.79 | $1.06 | x |
| 1998-12-31 | $10.44 | $1.06 | x |
| 1999-12-31 | $7.92 | $1.06 | x |
| 2000-12-31 | $6.48 | $1.06 | x |
| 2001-12-31 | $4.96 | $1.06 | x |
| 2002-12-31 | $4.34 | $1.06 | x |
| 2003-12-31 | $3.67 | $1.06 | x |
| 2004-12-31 | $3.56 | $1.06 | x |
| 2005-12-31 | $4.82 | $1.06 | x |
| 2006-12-31 | $8.26 | $1.06 | x |
| 2007-12-31 | $17.00 | $1.06 | x |
| 2008-12-31 | $9.40 | $1.06 | x |
| 2009-12-31 | $21.69 | $1.06 | x |
| 2010-12-31 | $20.03 | $1.06 | x |
| 2011-12-31 | $11.32 | $1.06 | x |
| 2012-12-31 | $-5.37 | $1.06 | x |
| 2013-12-31 | $0.20 | $1.06 | x |
| 2014-12-31 | $18.25 | $1.06 | x |
| 2015-12-31 | $13.79 | $1.06 | x |
| 2016-12-31 | $11.47 | $1.06 | x |
| 2017-12-31 | $7.12 | $1.06 | x |
| 2018-12-31 | $5.68 | $1.06 | x |
| 2019-12-31 | $3.67 | $1.06 | x |
| 2020-12-31 | $4.97 | $1.06 | x |
| 2021-12-31 | $0.30 | $1.06 | x |
| 2022-12-31 | $1.43 | $1.06 | x |
| 2023-12-31 | $0.91 | $1.06 | x |
| 2024-12-31 | $1.05 | $1.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rockwell Medical Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.47%
- • Asset Turnover: 1.71x
- • Equity Multiplier: 1.82x
- Recent ROE (-1.47%) is above the historical average (-385.40%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | -111.76% | -57.58% | 0.92x | 2.12x | $-2.07 Million |
| 1998 | -41.30% | -35.85% | 1.00x | 1.15x | $-2.36 Million |
| 1999 | -30.56% | -16.42% | 1.49x | 1.25x | $-1.46 Million |
| 2000 | -35.54% | -13.64% | 1.84x | 1.42x | $-1.30 Million |
| 2001 | -60.81% | -17.52% | 1.49x | 2.33x | $-1.84 Million |
| 2002 | -32.20% | -8.53% | 1.78x | 2.12x | $-1.29 Million |
| 2003 | 0.15% | 0.03% | 2.12x | 2.22x | $-312.36K |
| 2004 | 6.18% | 1.18% | 2.33x | 2.25x | $-130.71K |
| 2005 | 2.00% | 0.28% | 2.99x | 2.41x | $-307.67K |
| 2006 | -54.63% | -15.97% | 2.18x | 1.57x | $-5.41 Million |
| 2007 | -20.71% | -8.64% | 1.89x | 1.27x | $-5.51 Million |
| 2008 | -66.53% | -15.22% | 2.73x | 1.60x | $-9.05 Million |
| 2009 | -18.76% | -10.05% | 1.57x | 1.19x | $-8.43 Million |
| 2010 | -8.79% | -4.51% | 1.61x | 1.21x | $-5.74 Million |
| 2011 | -117.54% | -43.79% | 1.53x | 1.75x | $-23.27 Million |
| 2012 | 0.00% | -108.38% | 2.93x | 0.00x | $-53.03 Million |
| 2013 | -8191.46% | -93.13% | 1.44x | 61.06x | $-48.84 Million |
| 2014 | -31.04% | -39.36% | 0.55x | 1.43x | $-28.20 Million |
| 2015 | -23.14% | -26.05% | 0.63x | 1.41x | $-20.65 Million |
| 2016 | -37.39% | -37.16% | 0.64x | 1.57x | $-25.10 Million |
| 2017 | -78.76% | -45.24% | 0.97x | 1.79x | $-29.21 Million |
| 2018 | -117.78% | -50.68% | 1.21x | 1.93x | $-34.85 Million |
| 2019 | -167.95% | -55.67% | 1.38x | 2.18x | $-36.16 Million |
| 2020 | -90.40% | -49.66% | 0.80x | 2.28x | $-34.31 Million |
| 2021 | -1288.92% | -52.76% | 1.27x | 19.16x | $-32.93 Million |
| 2022 | -132.42% | -25.65% | 1.56x | 3.31x | $-20.09 Million |
| 2023 | -39.64% | -10.09% | 1.60x | 2.45x | $-10.57 Million |
| 2024 | -1.47% | -0.47% | 1.71x | 1.82x | $-3.74 Million |
Industry Comparison
This section compares Rockwell Medical Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rockwell Medical Inc (RMTI) | $37.02 Million | -111.76% | 0.55x | $37.35 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |